TORONTO, Sept. 14 /PRNewswire/ -- Data presented today from the world's
largest heart failure registry, known as ADHERE(R) (Acute Decompensated Heart
Failure National Registry), identified clinical indicators that may be used to
predict mortality risk in heart failure patients. These data were presented
today in a poster session at the Heart Failure Society of America (HFSA) 2004
Scientific Meeting in Toronto, Canada.
The ADHERE(R) analysis evaluated hospital data from 65,180 acutely
decompensated congestive heart failure patient cases to identify a combination
of clinical measures that distinguished heart failure patients who were at
high risk of in-hospital mortality from those at low risk. Key clinical
measures identified included: blood urea nitrogen levels (BUN), systolic
blood pressure (SBP), and serum creatinine (Cr).
Heart failure patients determined to have high risk of mortality were
identified with blood urea nitrogen (BUN) greater than or equal to 43 mg/dL,
systolic blood pressure (SBP) < 115 mm Hg, and serum creatinine (Cr) greater
than or equal to 2.75 mg/dL (20.5% average mortality rate, n=1,202). Heart
failure patients determined to have low risk of mortality (2.2% average
mortality rate, n=41,609) were identified with BUN < 43 mg/dL and SBP greater
than or equal to 115 mm Hg. Heart failure patients with intermediate risk of
mortality (6.75% average mortality rate, n=22,369) had less than three of the
high-risk markers and differed from the low risk group by at least one marker.
Additional differences in clinical characteristics between patients with
high or low risk of mortality were also identified such as age, sex, history
of coronary artery disease (CAD), history of atrial fibrillation and
in-hospital procedures.
"Clearly there are clinical measures that can be used to help predict
mortality risk in patients who are hospitalized with heart failure," said
Clyde W. Yancy, M.D., Professor of Medicine & Cardiology, Director of
Congestive Heart Failure/Heart Transplant Program at University of Texas
Southwestern Medical Center, Dallas, and principal investigator of the study.
"This ADHERE(R) observational study marks an important step towards
determining how heart failure patients might be better triaged and cared for
in-hospital, and how we might improve clinical outcomes, especially in
patients at high risk for mortality."
About the ADHERE(R) Study
The ADHERE(R) analysis, "Clinical Differences Between High and Low
Mortality Risk Stratified Patients Hospitalized With Acutely Decompensated
Heart Failure: ADHERE(R) Registry Data," (HFSA #414), compared differences in
clinical characteristics between patients classified as higher-risk and
lower-risk, as previously delineated by classification and regression tree
(CART) analysis. Analysis of variance (ANOVA) tests were used to compare
statistical means and Chi-square tests were used to compare proportions
between the high and low risk groups. The new analysis deciphered key clinical
indicators of in-hospital mortality risk in these patients.
"The goal of ADHERE is to improve treatment and outcomes for acutely
decompensated heart failure patients," said Gregg C. Fonarow, M.D., the Eliot
Corday Chair in Cardiovascular Medicine and Science, Director of the
Ahmanson-UCLA Cardiomyopathy Center and Professor of Medicine at UCLA, and
co-author of the study. "This analysis marks an important step towards this
goal by identifying key risk factors that may contribute to in-patient
mortality."
About ADHERE(R)
ADHERE(R) is a first-of-its-kind national registry that prospectively
collects observational data from across the United States in order to track
and study the medical management of patients hospitalized with acute heart
failure. The ADHERE(R) National Registry is sponsored by Scios Inc. and
overseen by an independent scientific advisory committee of nationally
recognized heart failure experts.
The ADHERE(R) Registry Core Module was launched in October 2001. It is a
multicenter, observational, open-label registry of the management of patients
treated in the hospital for acutely decompensated congestive heart failure
(CHF). ADHERE(R) is designed to help the medical community better understand
acute CHF, improve its management and enhance quality of care. Data regarding
current management and treatment trends is collected from the registry and
analyzed on a quarterly basis. These data and insights can be used by
individual hospitals to develop guidelines and protocols and increase the use
of evidence-based therapies to improve the standard of care among heart
failure patients, and potentially reduce costs.
To learn more about The ADHERE(R) Registry, call 866-616-2993, or e-mail
adhereinfo@sciosinc.com, or visit http://www.adhereregistry.com.
About Decompensated Congestive Heart Failure
According to the American Heart Association Heart Disease and Stroke
Statistics - 2004 Update, congestive heart failure affects more than
5 million Americans. It is estimated that the cost of treating congestive
heart failure patients in the U.S. will reach $28.8 billion in 2004.
Congestive heart failure is characterized by a progressive loss in the
heart's ability to pump blood. Since a weak heart does not pump fluid very
well through the body, fluid can back up and "pool" in the lungs causing
shortness of breath or can accumulate in the ankles causing swelling. This is
why heart failure is often called "congestive" heart failure, or CHF. The term
"decompensated" is a medical term used to describe patients with these
symptoms.
About Scios Inc.
Scios Inc., a Johnson & Johnson company, is a biopharmaceutical company
headquartered in Fremont, California. Scios is developing novel treatments for
cardiovascular disease, inflammatory disease and cancer. The Company's
disease-based technology platform integrates expertise in protein biology with
computational and medicinal chemistry to identify novel targets and rationally
design small molecule compounds and peptides for markets with unmet medical
needs. For more information, visit http://www.sciosinc.com.
HFSA Poster #414 Tuesday, September 14, 2004
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Chris B. Ernst of Scios Inc.,
+1-415-710-9445; or Karin Bauer Aranaz of WeissCom Partners,
Inc., +1-415-859-3414, for Scios Inc.
|
